U.S., April 11 -- ClinicalTrials.gov registry received information related to the study (NCT06921486) titled 'The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects' on March 28.
Brief Summary: This study is a multicenter, randomized, double-blind, placebo-controlled Phase IIb clinical trial aimed at evaluating the efficacy, safety, pharmacokinetics (PK), and immunogenicity profile of Efsubaglutide Alfa injection in overweight and obese subjects. The primary endpoint is the percentage change in body weight from baseline after 18 weeks of treatment.
Study Start Date: March 31
Study Type: INTERVENTIONAL
Condition:
Obesity and Overweight
Intervention:
DRUG: Efsubaglutide Alfa 5 mg QW
Efsubaglutide Alfa...